EGFR and non-small cell lung carcinoma: In 15–20% of NSCLC cases, mutations located in exon 19 and exon 21 of the epidermal growth factor receptor (EGFR) lead to constitutive activation, resulting in poor prognosis and short progression-free survival (PFS).